06.04.04

Express Mailing Label No.: EV 392155724 US

Attorney Docket No. 25669-020

Date of Deposit: June 2, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICANT:

Smith, et al.

SERIAL NUMBER:

10/797,821

EXAMINER:

Not Yet Assigned

FILING DATE:

March 9, 2004

ART UNIT:

Not Yet Assigned

For:

GLUCAN BINDING PROTEIN AND GLUCOSYLTRANSFERASE

IMMUNOGENS

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (4 pages), in duplicate;
- 3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25669-020. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306 Janine M. Susan, Reg. No. 46,119

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000 Fax: (617) 542-2241

Date: June 2, 2004

Express Mail Label No.: EV 392155724US

EDate of Deposit: June 2, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Smith, et al.

SERIAL NUMBER:

10/797,821

EXAMINER:

Not Yet Assigned

Attorney Docket No.: 25669-020

FILING DATE:

March 9, 2004

ART UNIT:

Not Yet Assigned

For:

GLUCAN BINDING PROTEIN AND GLUCOSYLTRANSFERASE

IMMUNOGENS

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Information Disclosure Statement is being submitted within three months of filing the application. Accordingly, no fee or certification is believed required. Copies of the references (*) are not provided as they were previously cited or submitted to the USPTO in prior applications, Serial No. 09/290,049, filed April 12, 1999 and Serial No. 10/383,930, filed March 7, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by

APPLICANT:

Smith, et al.

U.S.S.N.:

10/797,821

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25669-020.

Respectfully submitted,

Ingrid A. Beattie, Rleg. No. 42,306

Janine M. Susan, Reg. No. 46,119


Attorney(s) for Applicants MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000 Fax: (617) 542-2241

Date: June 2, 2004

TRA 1924595v1



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	10/797,821
	Filing Date	March 9, 2004
INFORMATION DISCLOSURE	First Named Inventor	Smith
STATEMENT BY APPLICANT	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	25669-020

	U.S. PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	4,150,116	04/17/79	Taubman, et al.	424	88	
	A2*	4,250,262	02/10/81	Taubman, et al.	435	193	
	A3*	4,438,200	03/20/84	Taubman, et al.	435	193	
	A4*	5,223,409	06/29/93	Ladner, et al.	435	69.7	
	A5*	5,686,075	11/11/97	Taubman, et al.	424	197.11	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*	wo	90/02809	PROTEIN ENGINEERING CORPORATION	03/22/90		
	B2*	wo	91/17271	AFFYMAX TECHNOLOGIES N.V.	11/14/91		
·	B3*	wo	92/01047	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED	01/23/92		
	B4*	wo	92/09690	GENENTECH, INC.	06/11/92		
	B5*	wo	92/15679	PROTEIN ENGINEERING CORPORATION	09/17/92		
	B6*	wo	92/18619	THE SCRIPPS RESEARCH INSTITUTE	10/29/92		
	B7*	wo	92/20791	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED	11/26/92		
	B8*	wo	93/01288	DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTILICHEN RECHTS	01/21/93	Abstract only	
	B9*	wo	99/07828		02/18/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
	C1*	Banas, et al., Infect. Immun., 58(3):667-673 (1990).		
	C2*	Banas, et al., FEMS Microbiol. Lett., 154:289-292 (1997).		
	C3*	Chia, et al., Infect. Immun., 61(11):4689-4695 (1993).		
	C4*	Chia, et al., Infect. Immun., 69(4):2493-2501 (2001).		
	C5*	Cole, et al., Monoclonal Antibodies and Cancer Therapy, pgs. 77-96 (1985).		

Page 2 of 4

Express Mail No.: EV 392155724 US
Date of Deposit: June 2, 2004

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C6*	Dertzbaugh, et al., Infect. Immun., 58(6):1509-1513 (1990).
	C7*	Dertzbaugh, et al., Infect. Immun., 58(1):70-79 (1990).
	C8*	Devulapalle, et al., <i>Protein Sci.</i> , 6:2489-2493 (1997).
	C9*	Ferretti, et al., J. Bacteriol., 169(9):4271-4278 (1987).
	C10*	Ferretti, et al., Infect. Immun., 56(6):1585-1588 (1988).
	C11*	Fuchs, et al., Biotechnology, 9:1369-1372 (1991).
	C12*	Funane, et al., <i>Biochem.</i> , 32:13696-13702 (1993).
	C13*	Furst, et al., Nucleic Acids Res., 17(16):6724 (1989).
	C14*	Galfre, et al., Nature, 266(5602):550-552 (1977).
_	C15*	GenBank Accession number AY046410 (2001).
	C16*	GenBank Accession number AY046411 (2001).
	C17*	GenBank Accession number AY046412 (2001).
	C18*	GenBank Accession number AY046413 (2001).
	C19*	GenBank Accession number AY046414 (2001).
	C20*	Griffiths, et al., EMBO J., 12(2):725-734 (1993).
	C21*	Hamada, et al., Microbiol. Rev., 44(2):331-384 (1980).
	C22*	Hay, et al., Hum. Antibod. Hybridomas, 3:81-85 (1992).
	C23*	Higgins, et al., CABIOS Communications, 5(2):151-153 (1989).
	C24*	Hopp, et al., Proc. Natl. Acad. Sci. USA, 78(6):3824-3828 (1981).
	C25*	Huse, et al., Science, 246:1275-1281 (1989).
	C26*	Jenkins, et al., FEBS Lett., 362:281-285 (1995).
	C27*	Jespergaard, et al., Infect. Immun., 67(2):810-816 (1999).
	C28*	Jespergaard, et al., Infect. Immun., 67(12):6543-6549 (1999).
	C29*	Keyes, et al., Arch. Oral Biol., 9:377-400 (1964).
	C30*	Köhler, et al., Nature, 266(5602):495-497 (1975).
	C31*	Kolenbrander, P.E., Annu. Rev. Microbiol., 54:413-437 (2000).
	C32*	Kuramitsu, et al., Archs. Oral Biol., 23(8):691-696 (1978).
	C33*	Lerner, E.A., Yale J. Biol. Med., 54(5):387-402 (1981).
	C34*	Loo, et al., J. Bacteriol., 182(5):1374-1382 (2000).
	C35*	Ma, et al., Eur. J. Immunol., 24:131-138 (1994).
	C36*	MacGregor, et al., FEBS Lett., 378:263-266 (1996).
	C37*	Matsuura, et al., <i>J. Biochem.</i> , 95:697-702 (1984).
	C38*	Mattos-Graner, et al., J. Dent. Res., 79(6):1371-1377 (2000).
	C39*	Mattos-Graner, et al., Infect. Immun., 69(11):6931-6941 (2001).
	C40*	Merrifield, R.B., Synthesis of a Tetrapeptide, 85:2149-2154 (1963).
	C41*	Mooser, et al., J. Dental Res., Abstract 1729, 69:325 (1990).
	C42*	Mooser, et al., J. Biol. Chem., 266(14):8916-8922 (1991).
	C43*	Navarre, et al., <i>Mol. Microbiol.</i> , 14(1):115-121 (1994).
-	C44*	Reinscheid, et al., <i>J. Bacteriol.</i> , 183(40:1175-1183 (2001).
	C45*	Russell, R.R.B., <i>J. Gen. Microbiol.</i> , 112:197-201 (1979).

Page 3 of 4

Express Mail No.: EV 392155724 US Date of Deposit: June 2, 2004

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C46*	Russell, et al., J. Dental Res., 67(3):543-547 (1988).			
	C47*	Sato, et al., Infect. Immun., 65(2):668-675 (1997).			
	C48*	Schubert, et al., Arch. Microbiol., 173(1):21-28 (2000).			
	C49*	Shimamura, et al., <i>J. Bacteriol.</i> , 176(16):4845-4850 (1994).			
	C50*	Shiroza, et al., J. Bacteriol., 169:4263-4270 (1987).			
	C51*	Smith, et al., Infect. Immun., 21(3):843-851 (1978).			
	C52*	Smith, et al., Infect. Immun., 23(2):446-452 (1979).			
	C53*	Smith, et al., Infect. Immun., 26(1):82-89 (1979).			
	C54*	Smith, et al., Infect. Immun., 28(2):441-450 (1980).			
	C55*	Smith, et al., Archs. Oral Biol., 26:871-878 (1981).			
	C56*	Smith, et al., Infect. Immun., 37(2):656-661(1982).			
	C57*	Smith, et al., Infect. Immun., 42(1):156-162 (1983).			
	C58*	Smith, et al., Infect. Immun., 55(11):2562-2569 (1987).			
	C59*	Smith, et al., Oral Microbiol. Immun., 5(2):57-62 (1990).			
	C60*	Smith, et al., J. Clin. Immunol., 10(5):273-281 (1990).			
	C61*	Smith, et al., Infect. Immun., 61(7):2899-2905 (1993).			
	C62*	Smith, et al., Oral Microbiol. Immun., 13(5):278-285 (1998).			
	C63*	Smith, et al., Infect. Immun., 62(6):2545-2552 (1994).			
	C64*	Smith, et al., Infect. Immun., 62(12):5470-5476 (1994).			
	C65*	Smith, et al., Oral Micro Immunol., 9:65-69 (1994).			
	C66*	Smith, et al., J. Dental Res., Abstract 818, 77:734 (1998).			
	C67*	Smith, et al., Infect. Immun., 67(5):2638-2642 (1999).			
	C68*	Smith, et al., J. Dental Res., 78:422 (1999).			
	C69*	Smith, et al., Oral Microbiol. Immunol., 15:124-130 (2000).			
	C70*	Smith, et al., Infect. Immun., 69(5):3135-3142 (2001).			
	C71*	Smith, et al., Infect. Immun., 69(8):4767-4773 (2001).			
<u> </u>	C72*	Smith, et al., Infect. Immun., 64(8):3069-3073 (1996).			
	C73*	Smith, et al., Infect. Immun., 65(11):4424-4430 (1997).			
	C74*	Socransky, et al., J. Clin. Microbiol., 22(2):303-305 (1985).			
	C75*	Søgaard, et al., J. Biol. Chem., 268(30):22480-22484 (1993).			
	C76*	Svendsen, et al., Lab. Anim. Sci., 45(1):89-93 (1995).			
<u> </u>	C77*	Tam, J.P., Proc. Natl. Acad. Sci. USA, 85(15):5409-5413 (1988).			
	C78*	Taubman, et al., <i>J. Immunol.</i> , 118(2):710-720 (1977).			
	C79*	Taubman, et al., Recent Advances in Mucosal Immunity, W. Strober, et al., eds. (NY Raven Press) pp. 371-382 (1982).			
	C80*	Taubman, et al., Glucosyltransferase, Glucans, Sucrose and Dental Caries, Doyle, et al., eds., Sp. Supp., Chemical Senses, pp. 249-258 (1983).			
	C81*	Taubman, et al., J. Oral Pathol., 17:466-470 (1988).			
	C82*	Taubman, et al., Infect. Immun., 63(8):3088-3093 (1995).			
	C83*	Taubman, et al., J. Dent. Res., Abstract 2666, 76:347 (1997).			
	C84*	Taubman, et al., Infect. Immun., 68(5):2698-2703 (2000).			

Page 4 of 4

Express Mail No.: EV 392155724 US Date of Deposit: June 2, 2004

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
Exam Initials Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C85*	Taubman, et al., Infect. Immun., 69:4210-4216 (2001).
	C86*	Tsumori, et al., <i>J. Bacteriol.</i> , 179(11):3391-3396 (1997).
	C87*	Ueda, et al., Gene, 69:101-109 (1988).
	C88*	U.S. non-published pending Patent Application No. 09/562,328 by Andrew Lees, Martin A. Taubman and Daniel J. Smith, filed May 1, 2000.
	C89*	U.S. Application No. 08/967,573 by Daniel J. Smith and Martin A. Taubman, filed November 10, 1997.
	C90*	Van Houte, et I., J. Dent. Res., 68(3):451-459 (1989).

^{*} a copy of this reference is not provided as it was previously cited by or submitted to the office in the prior applications, Serial No. 09/290,049, filed April 12, 1999, and Serial No. 10/383,930, filed March 7, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1924593v1